Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Orgenesis Inc (ORGS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 67,951
  • Shares Outstanding, K 15,621
  • Annual Sales, $ 18,660 K
  • Annual Income, $ -18,290 K
  • 60-Month Beta 0.64
  • Price/Sales 3.68
  • Price/Cash Flow N/A
  • Price/Book 3.21

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 02/28/19
See More
  • Average Estimate -0.22
  • Number of Estimates 2
  • High Estimate -0.14
  • Low Estimate -0.29
  • Prior Year -0.52
  • Growth Rate Est. (year over year) +57.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.23 +2.74%
on 05/23/19
4.90 -11.22%
on 05/01/19
-0.20 (-4.40%)
since 04/24/19
3-Month
4.23 +2.74%
on 05/23/19
5.93 -26.61%
on 03/25/19
-0.85 (-16.35%)
since 02/22/19
52-Week
3.87 +12.40%
on 12/24/18
9.50 -54.21%
on 06/13/18
-4.34 (-49.94%)
since 05/24/18

Most Recent Stories

More News
Orgenesis First Quarter 2019 Revenue Increases 177% to a Record $7.3 Million

Orgenesis Inc. (NASDAQ: ORGS) ("Orgenesis" or the "Company"), a developer, manufacturer and service provider of advanced cell therapies, today reported financial results and provided a business update...

ORGS : 4.35 (-1.14%)
Orgenesis Announces Planned Study to Confirm Suitability of Liver Cells as a Source for Personalized Cell Replacement Therapy for Insulin-Dependent Diabetic Patients

Orgenesis Inc. (NASDAQ: ORGS), a developer, manufacturer and service provider of advanced cell therapies, today announced it has received Institutional Review Board (IRB) approval to collect liver biopsies...

ORGS : 4.35 (-1.14%)
Hemogenyx Pharmaceuticals PLC Announces Final Results for the Year Ended 31 December 2018 - 29/04/2019

Hemogenyx Pharmaceuticals plc ("Hemogenyx" or the "Company")(LSE: HEMO), the biopharmaceutical group developing new therapies and treatments designed to transform bone marrow transplantation for the treatment...

ORGS : 4.35 (-1.14%)
Orgenesis Announces Collaboration and License Agreement for Exosome-Related Technologies with ExcellaBio

Orgenesis Inc. (NASDAQ: ORGS), a developer, manufacturer and service provider of advanced cell therapies, today announced that it has entered into a Collaboration and Licensing Agreement with ExcellaBio...

ORGS : 4.35 (-1.14%)
Will Orgenesis Inc. (ORGS) Report Negative Q1 Earnings? What You Should Know

Orgenesis Inc. (ORGS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ORGS : 4.35 (-1.14%)
Orgenesis Announces Collaboration with Digilab to Develop Industrial 3D Printing Capability for Cellular Structures and Tissues for Clinical Use

Orgenesis Inc. (NASDAQ: ORGS), a developer, manufacturer and service provider of advanced cell therapies, today announced that it has entered into a collaboration agreement with Digilab Inc. to develop...

ORGS : 4.35 (-1.14%)
Orgenesis Announces Publication of an Independent Study "The Role of The Vasculature Niche on Insulin Producing Cells Generated by Transdifferentiation of Adult Human Liver Cells" in the Stem Cell Research and Therapy Journal

Orgenesis Inc. (NASDAQ: ORGS), a developer of advanced cell therapies, manufacturer and service provider, today announced the publication of an independent study, entitled "The Role of The Vasculature...

ORGS : 4.35 (-1.14%)
Orgenesis Signs Master Service and Joint Venture Agreement with TheraCell Advanced Biotechnology for the Development of Cell and Gene Therapies

Orgenesis Inc. (NASDAQ: ORGS), a developer of advanced cell therapies, manufacturer and service provider, today announced that it has entered into a Master Service and Joint Venture Agreement (the "JV")...

ORGS : 4.35 (-1.14%)
Orgenesis Inc. Provides 2018 Corporate Highlights, Clinical Development and Growth Drivers for 2019 in New SNNLive Video Interview on StockNewsNow.com

LOS ANGELES, CA / ACCESSWIRE / March 27, 2019 / , The Official MicroCap News Source™, today published an SNNLive Video Interview with Vered Caplan, CEO of Orgenesis Inc. (OTCQB: ORGS), a developer, manufacturer...

ORGS : 4.35 (-1.14%)
Orgenesis Subsidiary Masthercell Global Announces Plans to Establish New Facility for Cell and Gene Therapy Commercial Manufacturing

Orgenesis Inc. (NASDAQ: ORGS), a developer of advanced cell therapies, manufacturer and service provider, today announced plans to establish a new, state-of-the-art production site for its Masthercell...

ORGS : 4.35 (-1.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade ORGS with:

Business Summary

Orgenesis, Inc. is a biopharmaceutical company. It focused on developing its trans-differentiation technologies for diabetes. The company deals with the combination of cell-based therapy and regenerative medicine into clinical development. Its operating segment consists of Contract Development and Manufacturing...

See More

Key Turning Points

2nd Resistance Point 4.49
1st Resistance Point 4.42
Last Price 4.35
1st Support Level 4.26
2nd Support Level 4.17

See More

52-Week High 9.50
Fibonacci 61.8% 7.35
Fibonacci 50% 6.68
Fibonacci 38.2% 6.02
Last Price 4.35
52-Week Low 3.87

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar